Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544515 | 0.83 | MAOA (0.46) | MAOAMAOBATMHDAC3HDAC4 | |
| SCHEMBL3430677 | 0.78 | ATM (0.44) | MAOAMAOBATMHDAC3HDAC4 | |
| SCHEMBL19458502 | 0.78 | MAOA (0.64) | MAOAMAOBATMHDAC3HDAC4 | |
| SCHEMBL16835547 | 0.76 | MAOA (0.61) | MAOAMAOBATMHDAC3HDAC4 | |
| SCHEMBL29056534 | 0.76 | MAOA (0.61) | MAOAMAOBATMHDAC3HDAC4 | |
| SCHEMBL8655488 | 0.75 | MAOA (0.40) | MAOAMAOBATMHDAC3HDAC4 | |
| SCHEMBL19885491 | 0.74 | MAOA (0.58) | MAOAMAOBATMHDAC3HDAC4 | |
| SCHEMBL521775 | 0.74 | MAOA (1.00) | MAOAMAOBATMHDAC3HDAC4 | |
| SCHEMBL22926733 | 0.74 | MAOA (0.58) | MAOAMAOBATMHDAC3HDAC4 | |
| SCHEMBL13715285 | 0.74 | MAOA (0.58) | MAOAMAOBATMHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116741953-A | Positive electrode active material, secondary battery, and electricity device | 宁德时代新能源科技股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2010103065-A1 | FUNGICIDAL COMPOSITIONS AND THEIR USE | BASF SE (DE) | 2010-09-16 | — | — | WO | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| CN-100569945-C | Be used to regulate the oligomeric compounds of BCL-2 | SANTARIS PHARMA AS (DK) | 2009-12-16 | — | — | CN | disclosed |
| CN-1918292-A | Oligomeric compounds for the modulation of bcl-2 | SANTARIS PHARMA AS (DK) | 2007-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | MAOA 4054/4885MAOB 3971/4885ATM 2713/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | MAOA 4054/4885MAOB 3971/4885ATM 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.